Tricyclic sulfonamides incorporating benzothiopyrano[4,3-c]pyrazole and pyridothiopyrano[4,3-c]pyrazole effectively inhibit alpha- and beta-carbonic anhydrase: X-ray crystallography and solution investigations on 15 isoforms.

Article Details

Citation Copy to clipboard

Marini AM, Maresca A, Aggarwal M, Orlandini E, Nencetti S, Da Settimo F, Salerno S, Simorini F, La Motta C, Taliani S, Nuti E, Scozzafava A, McKenna R, Rossello A, Supuran CT

J Med Chem. 2012 Nov 26;55(22):9619-29. doi: 10.1021/jm300878g. Epub 2012 Nov 8.

PubMed ID

23067387 [ View in PubMed

]

Abstract

Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous isozymes involved in crucial physiological and pathological events, representing the targets of inhibitors with several therapeutic applications. In this connection, we report a new class of carbonic anhydrase inhibitors, based on the thiopyrano-fused pyrazole scaffold to which a pendant 4-sulfamoylphenyl moiety was attached. The new sulfonamides 3a-e were designed as constrained analogues of celecoxib and valdecoxib. The most interesting feature of sulfonamides 3 was their predominantly strong inhibition of human (h) CA I and II, as well as those of the mycobacterial beta-class enzymes (Rv1284, Rv3273, and Rv3588c), whereas their inhibitory action against hCA III, IV, VA, VB, VI, VII, IX, XII, XIII, and XIV was found to be at least 2 orders of magnitude lower. X-ray crystallography and structural superposition studies made it possible to explain the very distinct inhibition profile of the tricyclic sulfonamides, different from those of celecoxib and valdecoxib.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Celecoxib	Carbonic anhydrase 2	Ki (nM)	21	N/A	N/A	Details
Celecoxib	Carbonic anhydrase 3	Ki (nM)	7400	N/A	N/A	Details
Valdecoxib	Carbonic anhydrase 2	Ki (nM)	43	N/A	N/A	Details
Valdecoxib	Carbonic anhydrase 3	Ki (nM)	78000	N/A	N/A	Details